Target Information

Target General Information

Top

Target ID

T80942 (Former ID: TTDI01565)

Target Name

Matrix metalloproteinase (MMP)

Synonyms

Matrix metalloproteinase

Click to Show/Hide

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 1 Target-related Diseases

Pediculosis [ICD-11: 1G00]

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 1 Approved Drugs

Abametapir

Drug Info

Approved

Head and body lice

[2]

Clinical Trial Drug(s)

[+] 2 Clinical Trial Drugs

BLZ-100

Drug Info

Phase 1/2

Glioma

[3]

S-3304

Drug Info

Phase 1/2

Solid tumour/cancer

[4]

Discontinued Drug(s)

[+] 13 Discontinued Drugs

ABT-518

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[5]

BB-2983

Drug Info

Discontinued in Phase 1

Inflammatory bowel disease

[6]

D-1927

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[7]

ONO-4817

Drug Info

Discontinued in Phase 1

Inflammatory bowel disease

[8], [9]

S-3536

Drug Info

Discontinued in Phase 1

Osteoarthritis

[10]

AG-2024

Drug Info

Terminated

Arthritis

[12]

AG-3296

Drug Info

Terminated

Solid tumour/cancer

[13]

BB-1433

Drug Info

Terminated

Arthritis

[14]

BE-16627B

Drug Info

Terminated

Inflammation

[15]

CP-471358

Drug Info

Terminated

Solid tumour/cancer

[16]

D-5410

Drug Info

Terminated

Rheumatoid arthritis

[17]

D-9120

Drug Info

Terminated

Inflammatory bowel disease

[18]

GI-129471

Drug Info

Terminated

Inflammation

[19]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

DFD-11

Drug Info

Application submitted

Head and body lice

[11]

Mode of Action

[+] 2 Modes of Action

Inhibitor

[+] 10 Inhibitor drugs

Abametapir

Drug Info

[2]

BLZ-100

Drug Info

[3]

S-3304

Drug Info

[1]

ABT-518

Drug Info

[20]

ONO-4817

Drug Info

[23]

S-3536

Drug Info

[24]

DFD-11

Drug Info

[11]

BB-1433

Drug Info

[26]

CP-471358

Drug Info

[28]

D-9120

Drug Info

[30]

Modulator

[+] 8 Modulator drugs

BB-2983

Drug Info

[21]

D-1927

Drug Info

[22]

AG-2024

Drug Info

[25]

AG-3296

Drug Info

[25]

BE-16627B

Drug Info

[27]

D-5410

Drug Info

[29]

GI-129471

Drug Info

[31]

PNU-248686A

Drug Info

[32]

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

References

Top

REF 1

Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020

REF 3

Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.

REF 4

ClinicalTrials.gov (NCT00078390) Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

REF 5

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015936)

REF 6

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006915)

REF 7

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008574)

REF 8

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6544).

REF 9

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014888)

REF 10

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019710)

REF 11

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 12

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009040)

REF 13

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007472)

REF 14

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012928)

REF 15

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006074)

REF 16

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011348)

REF 17

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007275)

REF 18

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013112)

REF 19

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006709)

REF 20

Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.

REF 21

Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.

REF 22

Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.

REF 23

ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.

REF 24

CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.

REF 25

US patent application no. 6,858,598, Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.

REF 26

Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing. Inflamm Res. 1997 Jun;46(6):211-5.

REF 27

Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int J Cancer. 1999 Aug 27;82(5):743-7.

REF 28

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42.

REF 29

US patent application no. US20080187572 A1.

REF 30

WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.

REF 31

Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp Cell Res. 2002 Apr 15;275(1):110-21.

REF 32

Determination of PNU-248686A, a novel matrix metalloproteinase inhibitor, in human plasma by liquid chromatography-tandem mass spectrometry, following protein precipitation in the 96-well plate format. J Chromatogr A. 2003 Feb 14;987(1-2):249-56.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN